Hologic Continues 2021 Spending Spree With $795M Acquisition Of Mobidiag
Mobidiag develops molecular diagnostic tests and instrumentation that will expand Hologic’s acute care testing capabilities.
You may also be interested in...
Following the purchase of Mobidiag, Hologic has aggressively launched the Novodiag platform across Europe in a bid to dominate the local molecular diagnostics market.
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.
PerkinElmer will add chemiluminescence products in endocrinology, autoimmunity and diagnostics to its portfolio with the planned buyout of Immunodiagnostics.